Paraneoplastic Pemphigus Antibody Screen (INACTIVE as of 11/15/21: Refer to 3004010 in the November Hotline)
Use as antibody panel for initial assessment and disease monitoring in paraneoplastic pemphigus, a rare paraneoplastic disease associated with lymphoproliferative disorders/malignancies and severe pemphigus clinical features with characteristic IgG antibodies detected on rodent substrates including rat bladder. Testing should be clinically supported and/or correlated with concurrent Cutaneous Direct Immunofluorescence, Biopsy (0092572).
Consider ordering concurrently with Immunobullous Disease Panel, Epithelial (3001409) for broad epithelial antibody testing; alternatively, order with Desmoglein 1 and Desmoglein 3 Antibodies in Pemphigus, IgG (0090649) and Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG (0092566); any of these epithelial antibodies may be increased in paraneoplastic pemphigus.
If other, more common, types of pemphigus are diagnostic considerations, order Pemphigus Antibody Panel, IgG (0090650) concurrently with this test.
If IgA paraneoplastic antibody testing is indicated, contact ARUP Client Services to request testing.
Semi-Quantitative Indirect Fluorescent Antibody (IFA)
New York DOH Approval Status
Plain red or serum separator tube (SST).
Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Hemolyzed or lipemic specimens.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely
The methodology is indirect immunofluorescence (IFA) of patient serum on substrates from rodents including mouse heart, liver, bladder and rat bladder to detect characteristic staining: intercalated discs in heart; portal tracts in liver; and simple columnar epithelium cell surface and basement membrane zone in bladders. For specimens less than 0.5 mL, call the Immunodermatology Laboratory at (866) 266-5699.
88346; 88350 x4
|Component Test Code*||Component Chart Name||LOINC|
|0092107||Paraneoplastic Pemphigus Ab Screen||42936-5|